Home/Pipeline/FMN riboswitch modulator

FMN riboswitch modulator

Infectious diseases

Pre-clinicalHit Identification

Key Facts

Indication

Infectious diseases

Phase

Pre-clinical

Status

Hit Identification

Company

Acellera

About Acellera

Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.

View full company profile

Therapeutic Areas

Oncology Immunology Inflammatory Diseases Infectious Diseases Neurology

Other Infectious diseases Drugs

Drug	Company	Phase	Status
inPROBE Platform	SDS Optic	Early R&D	Active
Potential Human POC Diagnostics	MatMaCorp	Research	Active
Nanoparticle Vaccines	Opko Health	Research	Active
Platform Vaccine Applications	Chimeron Bio	Discovery	Research
NP-G2-044	Novita Pharmaceuticals	Pre-Clinical	Exploratory
Ramoplanin™	Nanopharmaceutics	Clinical	Active
NanoDOX™	Nanopharmaceutics	Clinical	Active
Infectious Diseases	Menarini	Clinical	Active
Undisclosed Infectious Disease Program(s)	ATB therapeutics	Pre-clinical	Active
Vaccines for Infectious Diseases (undisclosed)	Takis	Pre-clinical	Active
Infectious Disease Diagnostics Program	Aptus Biosciences	Discovery	Active
Undisclosed Multispecific Therapeutics	ModeX Therapeutics	Pre-clinical	Active